BMS-984923

DRUG4 trials

Sponsors

Yale University, Allyx Therapeutics

Conditions

Alzheimer DiseaseAlzheimer's DiseaseDementiaDrug Drug Interaction (DDI)

Phase 1

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

CompletedNCT04805983

Yale UniversityAlzheimer Disease

Start: 2021-03-25End: 2022-04-24Updated: 2024-08-27

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

CompletedNCT05804383

Allyx TherapeuticsAlzheimer's Disease

Start: 2023-03-28End: 2025-10-15Updated: 2025-11-06

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

Allyx TherapeuticsAlzheimer Disease, Dementia

Start: 2023-01-10End: 2024-11-15Updated: 2024-07-30

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Active, not recruitingNCT06632990

Allyx TherapeuticsDrug Drug Interaction (DDI)

Start: 2024-11-04End: 2025-10-15Target: 36Updated: 2025-02-07